Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 19 04:00PM ET
21.60
Dollar change
+0.52
Percentage change
2.47
%
IndexRUT P/E- EPS (ttm)-0.28 Insider Own84.49% Shs Outstand737.09M Perf Week13.21%
Market Cap15.92B Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float114.29M Perf Month13.50%
Income-196.71M PEG- EPS next Q-0.08 Inst Own12.60% Short Float18.25% Perf Quarter11.05%
Sales0.00M P/S- EPS this Y70.17% Inst Trans13.01% Short Ratio9.60 Perf Half Y86.21%
Book/sh0.59 P/B36.36 EPS next Y-38.79% ROA-54.54% Short Interest20.86M Perf Year362.53%
Cash/sh0.66 P/C32.68 EPS next 5Y15.48% ROE-73.22% 52W Range2.10 - 33.89 Perf YTD21.04%
Dividend Est.- P/FCF- EPS past 5Y- ROI-44.49% 52W High-36.26% Beta-1.08
Dividend TTM- Quick Ratio8.31 Sales past 5Y-11.17% Gross Margin- 52W Low928.57% ATR (14)1.49
Dividend Ex-Date- Current Ratio8.31 EPS Y/Y TTM82.45% Oper. Margin- RSI (14)54.80 Volatility8.17% 7.57%
Employees105 Debt/Eq0.07 Sales Y/Y TTM-100.00% Profit Margin- Recom1.29 Target Price33.57
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-153.77% Payout- Rel Volume0.63 Prev Close21.08
Sales Surprise- EPS Surprise25.15% Sales Q/Q- EarningsFeb 24 BMO Avg Volume2.17M Price21.60
SMA200.09% SMA5010.04% SMA20042.04% Trades Volume1,363,694 Change2.47%
Date Action Analyst Rating Change Price Target Change
Jan-08-25Initiated Truist Buy $35
Dec-11-24Initiated Wells Fargo Overweight $30
Dec-06-24Initiated Jefferies Buy $31
Nov-04-24Initiated JMP Securities Mkt Outperform $32
Sep-27-24Downgrade Citigroup Buy → Neutral $19 → $23
Aug-12-24Initiated H.C. Wainwright Buy $16
May-07-24Initiated Citigroup Buy $7
Mar-26-24Initiated Stifel Buy $8
Jun-28-18Downgrade Janney Buy → Neutral
May-02-18Initiated Janney Buy
Feb-18-25 09:00AM
Feb-17-25 04:32AM
Feb-14-25 04:15PM
Feb-09-25 06:15AM
Feb-08-25 09:01AM
08:50AM Loading…
08:50AM
Feb-07-25 05:30AM
Feb-03-25 01:11PM
Jan-30-25 09:15AM
Jan-29-25 03:58PM
Jan-26-25 02:40AM
Jan-23-25 05:47AM
Jan-21-25 12:06PM
Jan-20-25 07:00PM
Jan-18-25 05:52PM
04:15PM Loading…
Jan-16-25 04:15PM
Jan-15-25 09:35AM
Jan-07-25 07:00AM
Jan-04-25 06:48AM
Jan-01-25 12:45PM
Dec-29-24 06:47AM
Dec-23-24 10:36AM
Dec-20-24 10:21AM
06:30AM
04:50AM
Dec-18-24 05:44AM
Dec-15-24 07:37AM
Dec-14-24 04:00PM
Dec-13-24 04:15PM
Dec-06-24 07:09PM
04:22AM Loading…
Dec-02-24 04:22AM
Nov-30-24 06:05AM
Nov-26-24 04:15PM
Nov-23-24 06:30AM
Nov-21-24 04:15PM
Nov-20-24 08:27AM
Nov-14-24 04:54PM
Nov-10-24 06:26PM
Nov-08-24 07:00AM
Nov-04-24 06:56PM
02:14PM
01:43PM
Nov-03-24 06:41AM
Oct-31-24 08:29AM
07:01AM
01:06AM
Oct-30-24 07:00AM
Oct-27-24 02:29PM
09:14AM
Oct-24-24 05:13AM
Oct-23-24 04:15PM
Oct-22-24 07:00AM
Oct-20-24 02:23PM
Oct-15-24 06:30AM
Oct-13-24 12:11PM
Oct-12-24 09:15AM
Oct-09-24 05:04PM
Oct-07-24 05:29AM
Oct-06-24 09:39AM
Oct-05-24 11:12AM
Oct-04-24 04:15PM
09:41AM
07:45AM
07:01AM
04:32AM
Oct-03-24 04:15PM
09:00AM
Oct-02-24 08:15AM
Sep-30-24 06:28AM
Sep-29-24 07:30AM
Sep-28-24 07:03AM
Sep-26-24 01:23AM
Sep-25-24 04:56AM
Sep-23-24 07:00AM
Sep-22-24 04:15PM
Sep-20-24 07:53AM
Sep-19-24 12:02PM
05:50AM
Sep-18-24 09:53AM
Sep-17-24 04:09PM
04:24AM
Sep-16-24 06:30AM
Sep-14-24 11:44AM
Sep-13-24 10:30AM
Sep-12-24 04:06PM
11:53AM
06:30AM
Sep-11-24 07:08PM
Sep-10-24 04:27AM
Sep-09-24 04:11PM
02:01PM
01:55PM
12:54PM
12:13PM
09:59AM
09:54AM
09:50AM
09:07AM
08:06AM
08:02AM
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7254,321201,87424,923,800Mar 27 08:28 PM
Zanganeh MahkamChief Executive OfficerMar 26 '24Buy3.7530,000112,50030,000Mar 27 08:28 PM
Zanganeh MahkamChief Executive OfficerMar 27 '24Buy3.7226,00096,720520,814Mar 27 08:28 PM
Dhingra AnkurChief Financial OfficerMar 26 '24Buy3.75100,000375,000354,958Mar 27 08:27 PM